Dhaka, Nov. 12 -- As weight-loss injections become a lucrative market for pharmaceutical companies, millions of people with diabetes in poorer countries are still struggling to obtain basic insulin treatment.

The growing market for weight-loss drugs could threaten insulin supplies, the head of the Access to Medicine Foundation has warned, The Guardian reports.

Jay Iyer, chief executive of the Netherlands-based non-profit, said companies could earn much higher profits from weight-loss medicines than from insulin.

He warned that if any of the three major insulin suppliers -- Sanofi, Eli Lilly or Novo Nordisk -- left the market, the consequences for patients could be severe, particularly for those with type 1 diabetes and insulin-dependen...